Post on 23-Dec-2015
1
OUR MISSIONTo reduce the burden of malaria in disease-endemic countries
by discovering, developing and facilitating access of new, effective and affordable anti-malaria medicines.
2
60 peopleGeneva-based
300 partnersAfrica 67
Americas 89Asia-Oceania 70
Europe 79
37 projects In pipeline
Research 21Translational 9Phase IIB/III 5
4 products launched>210 million
peopletreated
Syndicated investmentProjected funding: 1999 to 2017
4
Leveraging donor funds
MMV
£1.00
+
Pharma ‘in-kind’
£1.50 =
total
£3.50
Pharma ‘co-funding’
£1.00
TCP1 TCP2 TCP3a TCP3b TCP4
A Liver-stage schizontsB Blood-stage schizontsC GametocytesD Micro- and Macro-gametes/zygotesE OokinetesF OocystsG Sporozoites
P. cynomolgi hypnozoite assay BPRC, Netherlands
P. yoelii/berghei liver stage assayGNF Novartis/ UCSD, USA
In vitro blood stage activitySwiss TPH, Switzerland & Eskitis, Australia
Parasite Reduction Rate in vivo hu-SCID modelGSK Tres Cantos, Spain
Resistance risk assessmentColumbia University, USA
Gametocycte and gamete formation assaysGriffith University Australia and Imperial College UK
Gametocycte assayGSK Tres Cantos, Spain
Membrane feed assayImperial College, UK
Membrane feed assayTropIQ, NetherlandsGSK, Tres Cantos
MMV has assembled a network of partners/assays to select molecules with required properties
Network of partners/assays
Industry ●Academia ●
MMV–partnership pipeline Q1 2014
Focusing resourcesthrough early project prioritisation
4 2 41534
4 3 2942
Before GLPpreclinical
GLP preclinical Phase I Phase II Phase III Launched
Active
Terminated
Reducing costsin clinical development
INDUSTRY$180 MILLION
Industry estimates for clinicaldevelopment of an anti-infective
(Tufts)
MMV$54 MILLION*
Total clinical development costsfor pyronaridine-artesunate
* Includes direct internal project costs, CRO costs and MMV management & administration costs.
70%REDUCTION
INITIALCOST
PROPOSAL
Reducing partner & vendor costse.g. non-clinical toxicology study
INITIALCOST
PROPOSAL
CRO BID
Reducing partner & vendor costse.g. non-clinical toxicology study
73%REDUCTION
INITIALCOST
PROPOSAL
CRO BID
MMV SHARE
Reducing partner & vendor costse.g. non-clinical toxicology study
50%OF CRO BID
13%OF INITIALPROPOSAL
Access and affordability
ACT47%REDUCTION
Terms of MMV alliance agreements
+ Obligation to launch inmalaria-endemic countries
+ Price targets & cost audits
UK 23 pence* to treat one child
* cost for one 3-day course of Coartem-dispersible (Novartis public sector price for malaria-endemiccountries; weighted average treatment regimen 2012; March 1st 2013 exchange rate)
>212 million treatmentsdelivered and counting
Coartem Dispersible
60-87 million children cured200 million treatment courses delivered
* estimates based upon drug distribution data, epidemiology / testing data and clinical efficacy data(PCR-corrected 28-day cure rate for Coartem Dispersible)
Impact beyond malaria
Providing researchers with
400 anti-malaria compoundsto further R&D in other NTDs
Providing researchers with
400 anti-malaria compoundsto further R&D in other NTDs
3 chemical series
Providing researchers with
400 anti-malaria compoundsto further R&D in other NTDs
2 tropical diseasesSleeping sicknessLeishmaniasis
MMV is grateful for the financial support from the following organizations:
21